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Abstract
Background: The agitated behaviours that accompany dementia (e.g. pacing, aggression, calling out) are stressful
to both nursing home residents and their carers and are difficult to treat. Increasingly more attention is being paid
to alternative interventions that are associated with fewer risks than pharmacology. Lavandula angustifolia
(lavender) has been thought, for centuries, to have soothing properties, but the existing evidence is limited and
shows mixed results. The aim of the current study is to test the effectiveness of topically applied pure lavender oil
in reducing actual counts of challenging behaviours in nursing home residents.
Methods/Design: We will use a blinded repeated measures design with random cross-over between lavender oil
and placebo oil. Persons with moderate to severe dementia and associated behavioural problems living in aged
care facilities will be included in the study. Consented, willing participants will be assigned in random order to
lavender or placebo blocks for one week then switched to the other condition for the following week. In each
week the oils will be applied on three days with at least a two-day wash out period between conditions. Trained
observers will note presence of target behaviours and predominant type of affect displayed during the 30 minutes
before and the 60 minutes after application of the oil. Nursing staff will apply 1 ml of 30% high strength essential
lavender oil to reduce the risk of missing a true effect through under-dosing. The placebo will comprise of jojoba
oil only. The oils will be identical in appearance and texture, but can easily be identified by smell. For blinding
purposes, all staff involved in applying the oil or observing the resident will apply a masking cream containing a
mixture of lavender and other essential oils to their upper lip. In addition, nursing staff will wear a nose clip during
the few minutes it takes to massage the oil to the resident’s forearms.
Discussion: If our results show that the use of lavender oil is effective in reducing challenging behaviours in
individuals with dementia, it will potentially provide a safer intervention rather than reliance on pharmacology
alone. The study’s findings will translate easily to other countries and cultures.
Trial Registration: Australian New Zealand Clinical Trials Registry - ACTRN 12609000569202
Background
The challenging behaviours that accompany dementia
(e.g. pacing, aggression and calling out) can be stressful
for nursing home residents as well as their carers and
are difficult to treat. Such behaviours can be a conse-
quence of multiple causes. Some are due to pain,
depression or psychosis and require treatment with
analgesia or psychotropic medications. In other cases,
atypical antipsychotic medications are also the preferred
treatment [1] but have shown modest efficacy and can
have adverse effects such as increased confusion and
falls [2,3]. Therefore, novel treatments should be
explored. An example is Lavandula angustifolia (laven-
der) which has been thought, for centuries, to have
soothing properties that may affect the anxiety and
agitation that underlie the behavioural symptoms
associated with dementia.
Lavender is absorbed through skin and respiration and
acts on neurotransmitter systems. Linalool (an essential
ingredient of lavender) was shown by Elisabetsky et al.
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[4] to inhibit glutamate binding in rat cortex in a dose-
dependent fashion, consistent with its putative sedative
and anticonvulsant properties. When mice were exposed
to constant airborne lavender fragrance, their plasma
levels of linalool and linalyl acetate, the primary consti-
tuents of lavender, peaked at about 60 minutes [5].
Furthermore, rodents’ motor activity fell to 20% of base-
line levels within 30 minutes of exposure to lavender
fragrance and within 60 minutes, mice showed typically
“sedated” behaviour, crouching motionless in a corner
of their cage. When they were injected later with caf-
feine, a rise in motor activity was blocked by simulta-
neous exposure to lavender. Lemon balm and other
essential oils had much less effect [6].
In humans, plasma levels of linalool and linalyl acetate
rose quickly when 2% lavender oil was massaged into
abdominal skin over a 10 minute period [7]. Diego et al.
[8] exposed 40 university staff and students to lavender
and rosemary oils for periods of three minutes while
monitoring their EEG, mood state, attention and mathe-
matical accuracy. Lavender, but not rosemary, was asso-
ciated with improved mood and accuracy and with
increased frontal alpha power, consistent with drowsi-
ness. In a single case evaluation, Brooker et al. [9]
observed variable effects after treating four psychogeria-
tric patients for 10-minute periods on ten occasions
each with lavender oil by vapour, massage with a neutral
oil and vaporised lavender oil combined with massage.
When compared with ‘no treatment’ control sessions,
only one participant benefited to a statistically signifi-
cant degree and two became more agitated. Two other
case series suggested that lavender promotes sleep in
elderly people with dementia [10,11].
Three trials found no significant changes in beha-
vioural symptoms following exposure to lavender
[12-14], however two trials showed positive effects.
Holmes et al. [15] sprayed the communal area of a
dementia ward with either 2% Lavender oil or water
for two hours daily on alternating days. All 15 partici-
pants had severe dementia and daily agitation. An
observer wearing a nose clip rated behaviours using
the Pittsburgh Agitation Scale in the final hour of 10
sessions. Median behaviour scores were 20% lower
while exposed to lavender compared to water (p =
0.016). More recently, Lin et al. [16] administered
lavender or sunflower oils by vapour for an hour each
night while nursing home residents were asleep. All
70 participants had marked dementia with clinically
significant agitation. In a repeated measures study
with randomised cross-over, both oils were adminis-
tered for three week periods, with a two-week wash-
out between. Agitation scores fell by 7% with
lavender compared with less than 1% with sunflower
oil (p < 0.001).
A recent review concluded that while aromatherapy,
amongst other non-pharmacological treatments, was
identified as a potential treatment of behavioural
problems in dementia, studies were often weakened by
small sample sizes, lack of controls and imprecise mea-
sures [17]. Furthermore, previous studies generally failed
to specify source, purity, concentration and reliability of
delivery.
Therefore, the aim of the proposed study is to test the
effectiveness of topically applied 30% lavender oil of
proven purity as a treatment of behavioural symptoms
in dementia. To this end, we will conduct a rando-
mised-controlled trial (RCT) by way of a cross over
design with an appropriate control condition and
blinding. We hypothesise that lavender oil will lead to a
greater reduction in the frequency of behavioural symp-
toms of dementia than a placebo oil.
Methods/Design
Study design
We will test our hypothesis using a blinded, repeated
measures design with random cross-over between condi-
tions. Repeated measures RCTs minimise intra and
inter-individual differences since all participants are
subject to both conditions and behaviours vary greatly
in frequency within and between people with dementia
from hour to hour and day to day [17].
Ethical considerations
The protocol has been approved by the ethics commit-
tees of Monash University and all the respective health
organisations to which the participating aged care facil-
ities (ACFs) are affiliated (Southern Health, Peninsula
Health, St Vincent’s Health and Alfred Health).
It is most unlikely that participants can provide
informed consent. In Victoria, the “person responsible”
(usually a spouse or child) consents to the participation
of non-competent persons with dementia in non-
invasive studies. While the person responsible provides
written, informed consent to the study, persons with
dementia must assent to participation, as shown by their
willingness to have the oils applied.
Setting
The study will be conducted in mainstream and psycho-
geriatric ACFs in south-east Melbourne. Preference will
be given to larger facilities (≥60 beds).
Recruitment
Aged care facilities will be contacted by telephone to
explain the study. If ACFs show interest in the study,
researchers will visit the facility to provide all relevant
parties (Director of Nursing, nursing staff and diver-
sional therapists) with more detailed written and oral
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information. If facilities agree to participate in the study
then approval is sought from the relevant ethics com-
mittee. Following approval, a pre-selection screening is
conducted to identify eligible participants. An appointed
delegate of the ACF will then contact the person
responsible (PR) for each eligible person to ask if they
consent with the forwarding of their contact details to a
Monash University researcher. When verbal consent is
given, a senior researcher will contact the PR to explain
the study and answer queries. If a PR expresses interest
in the study they are sent a Participant Information and
Consent Form package, that includes detailed informa-
tion on the study procedure, a consent form and
pre-paid addressed return envelope. Once written con-
sent is received from the PR, researchers gather baseline
information to confirm eligibility of the person before
enrolment in the study.
Participants
Evidence suggests that verbally disruptive behaviours
(e.g. calling out) link more with lowered mood while
physically disruptive behaviours (e.g. pacing) link more
to a lack of meaningful occupation and socialisation
[18]. While these types of behaviours often occur
together, there is a trend to distinguish between them
for research purposes. The current study focuses on
physically disruptive behaviours, because they are more
common in ACFs. Selected participants must therefore
display at least one high frequency, physically agitated
behaviour that occurs daily at times other than during
nursing interventions, and to a degree that requires staff
intervention. Up to two target behaviours will be
selected per participant in discussion with nursing staff
based on frequency and severity using the Cohen Mans-
field Agitation Inventory [19].
Inclusion criteria
(1) A chart diagnosis of moderate to severe dementia.
(2) Standard cognitive tests are invalid in this group
since most participants will be severely impaired. Many
will score zero on the widely used Mini-Mental State
Examination [20]. The chart diagnosis of dementia will
additionally be confirmed by interviewing staff with the
Clinical Dementia Rating [21].
(3) At least one high frequency behavioural symptom
as described above.
(4) An assessment by the ACF staff, GP and/or
psychiatrist that behaviours are not due primarily to
untreated or inadequately treated pain, physical illness,
major depression or psychosis.
(5) Residence in a high care, or mixed high care and
low care ACF for three or more months.
(6) Consent to the study by the PR as defined by the
Victorian Civil and Administrative Tribunal.
Exclusion criteria
(1) Active treatment that might change over the study
period by a psychiatrist or aged mental health team.
(2) A current, acutely life-threatening physical illness
as reported by ACF staff and the GP.
(3) Behaviours that present a hazard to researchers
(e.g. unpredictable aggression).
(4) A medical condition (e.g. dermatitis) that precludes
the use of topical oil.
Interventions
Consented, willing participants will be assigned in
random order to one block of 30% lavender oil and one
block of neutral control oil. Each block will last for
three days (i.e. 3 observation/treatment periods) over a
week to capture possible cumulative benefits, with at
least a two-day washout period between each block.
Thus, in total there will be 6 observations/treatment
periods over a 2 week period. Interventions will be
delivered at times when nursing staff report that the tar-
get behaviour/s are of high frequency (excluding times
of personal nursing care).
A nurse will massage 1.0 ml of the 30% lavender or
control oil into the resident’s forearms for one minute.
Based on an earlier study, we expect that lavender
plasma levels will peak 20 minutes later and have faded
by 90 minutes [7]. Observations will commence 30 min-
utes pre-exposure and finish 60 minutes post treatment,
giving a total observation period of 90 minutes per ses-
sion. A longer period is not feasible due to interruptions
for nursing care, meals, visitors etc.
Materials
Aromatherapy will fail if the quantities of essential oil
are too small to be effective. When applied by massage,
lavender is typically prescribed as a 2.5% oil or lotion
but there is no evidence to support this choice. We will
apply 1 ml of 30% preparation to reduce the risk of
missing a true effect through under-dosing. Pure laven-
der oil will be supplied by Essential Therapeutics,
Melbourne, whose chemist will verify its purity using
gas chromatography and supply a report to this effect.
The characteristic profile of pure lavender’s constituents
is readily available [7].
Many varieties of pure lavender are held in stock. To
select the one with greatest biological activity, up to
6 varieties will be assayed by Prof. George Lees (Depart-
ment of Pharmacology and Toxicology, Otago Univer-
sity) who will measure the changes induced by 1:1000
dilutions of oils on the synaptic currents and action
potentials of cultured networks of rat embryo pyramidal
cortical neurones. The assays measure the capacity of
samples to exert depressant effects on neurones, thus
providing an animal model of sedation. The same assays
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have been used to demonstrate the mode of action of
licensed antidepressants [22] and sedatives [23,24].
The selected pure lavender oil will then be diluted
with jojoba oil. The control oil will comprise just the
base ingredients and will be tested to ensure that it is
biologically inert. The supplied products will be stored
in opaque containers at the recommended temperature.
Outcomes measures
A discretely positioned, trained researcher will record if
the selected physically agitated behaviour is present or
absent at one-minute intervals over the 90-minute
observation period. Behaviour counts will range from
zero to 30 in the before intervention period and zero to
60 in the after intervention period. This method was
used successfully in previous studies with high levels of
inter-rater reliability [2,25-28].
The primary measure in this trial will be the change
in mean counts of physically agitated behaviours before
and after intervention phases.
Secondary measures will include:
(a) A rating scale completed by the observing
researcher during the 90 minute observation period at
one-minute intervals of the participant’s predominant
type of affect. We will include three positive emotions
(pleasure, contentment and interest), one neutral and
three negative emotions (anger, sadness and fear/anxi-
ety) [29].
(b) The 29-item Cohen-Mansfield Agitation Inventory
[19] completed by the researcher in discussion with
nursing staff in closest contact with the resident at the
end of each week, relating to behaviour in the preceding
week. Where possible, the same staff members will be
questioned on each occasion.
(c) The proportion of residential facilities that con-
tinue to administer lavender as a treatment for agitation
after the end of the trial.
(d) The cost of materials.
Blinding and reliability
The order of conditions will be generated randomly
using Random Number selection in Excel. An indepen-
dent researcher will prepare the oil vials and no member
of the lavender research team will have access to the
code until the trial is completed.
The oils will be identical in appearance and texture,
but nursing staff and possibly even the observers may
detect by smell which treatment condition has been
applied. To exclude this possibility, both the individual
applying the oil and the observer will (at regular inter-
vals) apply a cream containing a mixture of lavender
and other essential oils (e.g. rosemary) to their upper
lip while measuring participants’ behaviour. In addi-
tion, nursing staff will wear a nose clip during the few
minutes it takes to apply the oil to the resident ’s
forearms.
Behaviour counts require some judgement and
observers must be trained and monitored. To ensure
high reliability (kappa > .90), a second research assistant
will co-rate behaviours in the initial sessions following
training by an experienced observer. Subsequent debrief-
ing sessions and repeated co-rating will determine how
much joint training and supervision is required to
achieve this level of agreement.
Sample size calculation
Sample size was calculated for the primary outcome
measure (physically agitated behaviour) for a two-sided
hypothesis test with a Type I error rate of 0.05 and a
Type II error rate of 0.10 (90% power). In the following
calculations, we used estimates for this outcome mea-
sure from a repeated measures study we conducted of
family simulated presence therapy in a similar popula-
tion [25]. In that study, the largest effect was achieved
with simulated presence (effect size 0.45 relative to an
attention control condition) with individualised music
achieving a smaller effect size (effect size 0.32 relative to
control). Given the mixed evidence supporting lavender
oil, it seems prudent to apply the smaller effect of
individualised music in the current study.
In the 30-minute baseline observation period, we
anticipate that participants will display a mean count of
5.0 physically agitated behaviours per observation period
with a standard deviation of 2.15. We anticipate a mean
improvement of 0.69 behaviours per period during the
control intervention compared with a mean improve-
ment of 1.23 per period with lavender, giving a differ-
ence of 0.54 between the conditions (effect size 0.32).
Based on data from our previous study, we estimate a
within-person correlation of 0.70. A sample of 77 parti-
cipants will be required to detect this difference, assum-
ing the same variance (SD = 2.15) across conditions.
Based on earlier experience and the brief duration of
this study we expect 10% attrition and so will recruit 85
participants.
Statistical analysis
We will use two-way repeated measures analysis of
variance to test the significance of changes in the num-
ber of physically agitated behaviours over time (before
and after treatment). We will use simple main effects to
determine the specific effect of lavender relative to the
control condition and we will test for the interaction
between treatment and time. Simple contrasts will be
used to tease out more detailed relationships, including
testing the primary hypothesis that lavender oil
reduces the frequency of physically agitated behaviours
significantly more than a plausible control. Baseline
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characteristics of participants who drop out during the
study will be compared to those who complete it to
assess patterns of loss to follow-up and provide insights
into the degree to which results can be generalised.
Discussion
The proposed study will help meet the need for better
controlled trials of alternative treatments for agitated
behaviours associated with dementia. Our findings may
guide family and professional carers in their selection of
available evidence-based ways to reduce stressful beha-
vioural symptoms that respond only partially to psycho-
tropic medications. If our results show that use of
Lavender oil is effective in reducing challenging beha-
viours in individuals with dementia, it will potentially
provide a safer intervention rather than reliance on
pharmacology alone. The study’s findings will translate
easily to other countries and cultures.
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